Status:
COMPLETED
Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy
Lead Sponsor:
NovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Heart Failure, Congestive
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the effect of KW-3902IV, in addition to standard therapy, on the proportion of worsening heart failure and worsening renal function, and on the proportion of deaths or rehospitalizations f...
Detailed Description
Loop diuretics are generally first line therapy in patients hospitalized with acute heart failure syndrome (AHFS). Their use far exceeds that of vasoactive agents. Tubuloglomerular feedback (TGF) is t...
Eligibility Criteria
Inclusion
- Dyspnea at rest or with minimal exertion at randomization
- Fluid overload
- Estimated creatinine clearance (CrCl) between 20-60 mL/min
- Worsening renal function
- Anticipated need for IV diuretic treatment for at least 48 hours after the start of study drug
- BNP \>500 pg/mL or NT-pro-BNP \>2000 pg/mL
- Systolic blood pressure ≥90 mmHg at randomization
Exclusion
- IV radiographic contrast within 14 days
- IV vasodilators within 6 hours
- Serum potassium \<3.5 meq/L
- Ongoing or planned therapy for heart failure with mechanical circulatory or ventilatory support
- Ongoing or planned treatment with ultrafiltration, hemofiltration, or dialysis
- Rapidly progressive acute renal failure
- Evidence of acute tubular necrosis or post-obstructive nephropathy or other exogenous causes of acute kidney injury, unrelated to heart failure
- Severe pulmonary disease
- Significant stenotic mitral or aortic valvular disease
- Heart transplant recipient or admitted for cardiac transplantation or LVAD surgery
- Any major surgery within 2 weeks prior
- evidence of acute coronary syndrome in the 2 weeks prior
- Hgb \<8 g/dL, Hct \<25%, or active bleeding requiring transfusion
- Acute myocarditis or hypertrophic obstructive, restrictive, or constrictive cardiomyopathy.
- Known hepatic impairment
- Non-cardiac pulmonary edema
- Temperature \>38°C
- Sepsis or active infection requiring IV anti-microbial treatment
- Administration of an investigational drug or device within 30 days
- Current or anticipated therapy with atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, or voriconazole
- Administration of any vasopressor or inotropic drug within 72 hours
- History of seizure (except febrile seizure)
- Stroke within 2 years
- History of brain tumor of any etiology
- Brain surgery within 2 years
- Encephalitis/meningitis within 2 years
- History of penetrating head trauma
- Closed head injury with loss of consciousness (LOC) over 30 minutes within 2 years
- History of or at risk for alcohol withdrawal seizures
- Advanced Alzheimer's disease
- Advanced multiple sclerosis
Key Trial Info
Start Date :
August 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
480 Patients enrolled
Trial Details
Trial ID
NCT00443690
Start Date
August 1 2007
End Date
January 1 2009
Last Update
February 20 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.